Materials of the II Conference “Current Issues of Diagnosis and Treatment of Ph-Negative and Ph-Positive Myeloproliferative Neoplasms” (March 15–16, 2019; National Research Center for Hematology, Moscow)

AL Melikyan1, AG Turkina1, IN Subortseva1, EYu Chelysheva1, AM Kovrigina1, VA Shuvaev2, VV Baikov3, OYu Vinogradova4,5,6, SM Kulikov1, AN Petrova1, AV Bykova1, A-PA Poshivai2, YuYu Vlasova3, MM Chukavina7, OD Serdyuk8, KV Naumova9, NT Siordiya10, NS Lazorko10, RV Grozov10, EI Mullo11, AS Maksimova12, OM Senderova13, OV Kanya13, MS Fominykh2,25, DI Shikhbabaeva4, EA Belyakova14, IS Martynkevich2, LB Polushkina2, MN Zenina2, EV Efremova2, VI Rugal2, LP Papayan2, NE Korsakova2, OYu Matvienko2, EB Syrtseva15, SV Gappoev16, MV Barabanshchikova3, MO Ivanova3, KD Kaplanov17, ES Rogova9, KB Trizna18, AS Zhevnyak19, OE Ochirova20, AA Shakhaeva20, AS Lyamkina21, IP Mikhno22, YuB Chernykh23, TV Chudanova23, IN Kontievskii23, NN Glonina24, MV Burundukova22

1 National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

2 Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024

3 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022

4 SP Botkin Municipal Clinical Hospital, 5 2-i Botkinskii pr-d, Moscow, Russian Federation, 125284

5 Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela str., Moscow, Russian Federation, 117997

6 NI Pirogov Russian National Research Medical University, 1 Ostrovityanova str., Moscow, Russian Federation, 117997

7 Kolomenskaya Central Regional Hospital, 318 Oktyabrskoi revolyutsii str., Kolomna, Moscow Region, Russian Federation, 140401

8 Clinical Oncology Dispensary No. 1, 146 Dimitrova str., Krasnodar, Russian Federation, 350040

9 Samara State Medical University, 165b Karla Marksa pr-t, Samara, Russian Federation, 443086

10 VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341

11 Chekhov Regional Hospital No. 2, 37 Gagarina str., Chekhov, Moscow Region, Russian Federation, 142300

12 Municipal Clinical Hospital No. 16, 121 Gagarina str., Kazan, Russian Federation, 420039

13 Irkutsk Regional Clinical Hospital, 100 Yubileinyi microdistrict, Irkutsk, Russian Federation, 664049

14 II Mechnikov North-Western State Medical University, 41 Kirochnaya str., Saint Petersburg, Russian Federation, 191015

15 Krasnoyarsk Interdistrict Municipal Hospital No. 7, 4 Akademika Pavlova str., Krasnoyarsk, Russian Federation, 660003

16 Krasnoyarsk Pathology Bureau, 3d Partizana Zheleznyaka str., Krasnoyarsk, Russian Federation, 660022

17 Volgograd Regional Clinical Oncology Dispensary No. 1, 78 Zemlyachki str., Volgograd, Russian Federation, 400138

18 Tomsk Regional Clinical Hospital, 96 Ivana Chernykh str., Tomsk, Russian Federation, 634063

19 Pathology Bureau, 96 Ivana Chernykh str., Tomsk, Russian Federation, 634063

20 NA Semashko Republican Clinical Hospital, 12 Pavlova str., Ulan-Ude, Russian Federation, 670031

21 Novosibirsk State Medical University, 52 Krasnyi pr-t, Novosibirsk, Russian Federation, 630091

22 Municipal Clinical Hospital No. 2, 21 Polzunova str., Novosibirsk, Russian Federation, 630051

23 NF Vladimirskii Moscow Regional Research Clinical Institute, 61/2 Shchepkina str., Moscow, Russian Federation, 129110

24 SI Sergeev Clinical Hospital No. 1, 9 Krasnodarskaya str., Khabarovsk, Russian Federation, 680009

25 Saint Petersburg State University, 7-9 Universitetskaya nab., Saint Petersburg, Russian Federation, 199034

For correspondence: Irina Nikolaevna Subortseva, MD, PhD, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; e-mail: soubortseva@yandex.ru

For citation: Melikyan AL, Turkina AG, Subortseva IN, et al. Materials of the II Conference “Current Issues of Diagnosis and Treatment of Ph-Negative and Ph-Positive Myeloproliferative Neoplasms” (March 15–16, 2019; National Research Center for Hematology, Moscow). Clinical oncohematology. 2020;13(2):199–231 (In Russ).


ABSTRACT

The publication contains materials of the reports presented at the II Conference “Current Issues of Diagnosis and Treatment of Ph-Negative and Ph-Positive Myeloproliferative Neoplasms” held from 15 to 16 March 2019 at the National Research Center for Hematology (Moscow). The conference was organized to enable professional communication of the clinicians specializing in the treatment of myeloproliferative neoplasms (MPN), and the researchers in the related fields as well as to allow the exchange of views on the implementation of current diagnosis and treatment methods in Ph-negative and Ph-positive MPNs. Reports covered a wide range of rare and non-standard settings. Of particular importance was the opportunity to debate them in detail at panel discussions and interactive sessions. This format of the conference allowed to provide expert opinions in the present publication. It emphasizes the importance of complex diagnosis in MPN using morphological examination of bone marrow core biopsy samples and molecular genetic testing. Accordingly, the second day of the conference was devoted to a thorough analysis of the morphological characteristics of the cases presented and based on bone marrow core biopsy samples.

Keywords: myeloproliferative neoplasms, chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, primary myelofibrosis, thrombosis, JAK2V617F, CALR, MPL, next-generation sequencing, ruxolitinib.

Received: September 30, 2019

Accepted: March 5, 2020

Read in PDF


REFERENCES

  1. Rychter A, Jerzmanowski P, Holub A, et al. Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors. Med Oncol. 2017;34(6):104. doi: 10.1007/s12032-017-0958-6.

  2. Челышева Е.Ю., Галактионова А.В., Туркина А.Г. Проблема приверженности терапии хронического миелолейкоза: понять пациента и найти решения. Клиническая онкогематология. 2013;6(2):157–65.

    [Chelysheva EYu, Galaktionova AV, Turkina AG. The problem of adherence to therapy in chronic myeloid leukemia: understanding the patient and making a decision. Klinicheskaya onkogematologiya. 2013;6(2):157–65. (In Russ)]

  3. Туркина А.Г., Зарицкий А.Ю., Шуваев В.А. и др. Клинические рекомендации по диагностике и лечению хронического миелолейкоза. Клиническая онкогематология. 2017;10(3):294–316. doi: 10.21320/2500-2139-2017-10-3-294-316.

    [Turkina AG, Zaritskii AYu, Shuvaev VA, et al. Clinical Recommendations for the Diagnosis and Treatment of Chronic Myeloid Leukemia. Clinical oncohematology. 2017;10(3):294–316. doi: 10.21320/2500-2139-2017-10-3-294-316. (In Russ)]

  4. Deininger MW, Cortes J, Paquette R, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer. 2007;110(7):1509–19. doi: 10.1002/cncr.22936.

  5. Richter J, Soderlund S, Lubking A, et al. Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome? J Clin Oncol. 2014;32(25):2821–3. doi: 10.1200/jco.2014.55.6910.

  6. Туркина А.Г., Немченко И.С., Челышева Е.Ю. и др. Национальные клинические рекомендации: диагностика и лечение миелопролиферативных заболеваний с эозинофилией и идиопатического гиперэозинофильного синдрома. Гематология и трансфузиология. 2016;61(3):1–24.

    [Turkina AG, Nemchenko IS, Chelysheva EYu, et al. National clinical guidelines: Diagnosis and treatment of myeloproliferative neoplasms with eosinophilia and idiopathic hypereosinophilic syndrome. Gematologiya i transfuziologiya. 2016;61(3):1–24. (In Russ)]

  7. Samuelson BT, Vesely SK, Chai-Adisaksopha C, et al. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinol. 2016;27(6):648–52. doi: 10.1097/MBC.0000000000000446.

  8. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. doi: 10.1182/blood-2016-06-721662.

  9. Меликян А.Л., Туркина А.Г., Ковригина А.М. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2016 г.). Гематология и трансфузиология. 2017;1:25–60.

    [Melikyan AL, Turkina AG, Kovrigina AM, et al. Clinical guidelines on diagnosis and treatment of Ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, and primary myelofibrosis) (2016 edition). Gematologiya i transfuziologiya. 2017;1:25–60. (In Russ)]

  10. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32. doi: 10.1200/jco.2005.07.062.

  11. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5(11):e369. doi: 10.1038/bcj.2015.94.

  12. Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062–9. doi: 10.1182/blood-2014-05-578435.

  13. Tefferi A, Lasho TL, Tischer A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood. 2014;124(15):2465–6. doi: 10.1182/blood-2014-07-588426.

  14. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494–500. doi: 10.1038/leu.2014.57.

  15. Полушкина Л.Б., Мартынкевич И.С., Шуваев В.А. и др. Молекулярно-генетические и цитогенетические особенности первичного миелофиброза. Гены и клетки. 2016;11(3):113–22.

    [Polushkina LB, Martynkevich IS, Shuvaev VA, et al. Molecular genetic and cytogenetic characteristics of primary Geny i kletki. 2016;11(3):113–22. (In Russ)]

  16. Tefferi A, Lasho TL, Finke CM, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1(2):105–11. doi: 10.1182/bloodadvances.2016000208.

  17. Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156. doi: 10.1186/s13045-017-0527-7.

  18. Vannucchi AM, Guglielmelli P, Rotunno G, et al. Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. 2014;124(21):405. doi: 10.1182/blood.v124.21.405.405.

  19. Wei JJ, Kallenbach LR, Kreider M, et al. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep. 2019;5(4):360–1. doi: 10.1016/j.jdcr.2019.02.006.

  20. Garcia-Pagan JC, Buscarini E, Janssen HLA, et al. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol. 2016;64(1):179–202. doi: 10.1016/j.jhep.2015.07.040.

  21. Шмаков Р.Г., Полушкина Е.С. Особенности репродуктивной функции у женщин с онкогематологическими заболеваниями. Современная онкология. 2008;10(3):68–9.

    [Shmakov RG, Polushkina ES. Reproductive function characteristics in women with oncohematological diseases. Sovremennaya onkologiya. 2008;10(3):68–9. (In Russ)]

  22. Griesshammer M, Sadjadian P, Wille K. Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy. Expert Rev Hematol. 2018;11(9):697–706. doi: 10.1080/17474086.2018.1506325.

  23. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev. 2019;33:74–81. doi: 10.1016/j.blre.2018.07.004.